Overcoming toxicities when combining PI3K inhibitors with other treatments - 101793

Spotlight
Video

Overcoming toxicities when combining PI3K inhibitors with other treatments

VJHemOnc has 872 videos Subscribe Here

Loading........
Description: Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different combination studies with idelalisib, and how we are trying to overcome toxicities found, by developing second-generation PI3K inhibitors, such as copanlisib, umbralisib, and duvelisib.
Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 annual meeting, held in Vancouver, BC, Canada.
Shared By : VJHemOnc
Posted on : 11/17/17
Added : 2 months ago
Category : Lymphoma



Recommended

Nothing found.

More From VJHemOnc

Nothing found.